Proteome Changes in Platelets After Pathogen Inactivation-An Interlaboratory Consensus

被引:73
作者
Prudent, Michel [1 ]
D'Alessandro, Angelo [2 ]
Cazenave, Jean-Pierre [3 ]
Devine, Dana V. [4 ,5 ]
Gachet, Christian [3 ]
Greinacher, Andreas [6 ]
Lion, Niels [1 ]
Schubert, Peter [4 ,5 ]
Steil, Leif
Thiele, Thomas [6 ]
Tissot, Jean-Daniel [1 ]
Voelker, Uwe [7 ]
Zolla, Lello [2 ]
机构
[1] Serv Reg Vaudois Transfus Sanguine, Unite Rech & Dev, CH-1066 Epalinges, Switzerland
[2] Univ Tuscia, Largo Univ, Dept Ecol & Biol Sci, Viterbo, Italy
[3] Univ Strasbourg, Etab Francais Sang Alsace, INSERM, UMR S949, Strasbourg, France
[4] Univ British Columbia, Ctr Innovat, Canadian Blood Serv, Vancouver, BC V5Z 1M9, Canada
[5] Univ British Columbia, Dept Pathol & Lab Med, Ctr Blood Res, Vancouver, BC V5Z 1M9, Canada
[6] Univ Med Greifswald, Inst Immunol & Transfus Med, Greifswald, Germany
[7] Univ Med Greifswald, Interfak Inst Genet & Funkt Genomforsch, Greifswald, Germany
关键词
SPECTROMETRY-BASED PROTEOMICS; ULTRAVIOLET-LIGHT TREATMENT; INTEGRIN-LINKED KINASE; AMOTOSALEN-HCL S-59; P38 MAP KINASE; THERAPEUTIC-EFFICACY; PHOTOCHEMICAL INACTIVATION; APHERESIS PLATELETS; REDUCTION TREATMENT; GAMMA-IRRADIATION;
D O I
10.1016/j.tmrv.2014.02.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pathogen inactivation (PI) of platelet concentrates (PCs) reduces the proliferation/replication of a large range of bacteria, viruses, and parasites as well as residual leucocytes. Pathogen-inactivated PCs were evaluated in various clinical trials showing their efficacy and safety. Today, there is some debate over the hemostatic activity of treated PCs as the overall survival of PI platelets seems to be somewhat reduced, and in vitro measurements have identified some alterations in platelet function. Although the specific lesions resulting from PI of PCs are still not fully understood, proteomic studies have revealed Potential damages at the protein level. This review merges the key findings of the proteomic analyses of PCs treated by the Mirasol Pathogen Reduction Technology, the Intercept Blood System, and the Theraflex UV-C system, respectively, and discusses the potential impact on the biological functions of platelets. The complementarities of the applied proteomic approaches allow the coverage of a wide range of proteins and provide a comprehensive overview of PI-mediated protein damage. It emerges that there is a relatively weak impact of PI on the overall proteome of platelets. However, some data show that the different PI treatments lead to an acceleration of platelet storage lesions, which is in agreement with the current model of platelet storage lesion in pathogen-inactivated PCs. Overall, the impact of the PI treatment on the proteome appears to be different among the PI systems. Mirasol impacts adhesion and platelet shape change, whereas Intercept seems to impact proteins of intracellular platelet activation pathways. Theraflex influences platelet shape change and aggregation, but the data reported to date are limited. This information provides the basis to understand the impact of different PI on the molecular mechanisms of platelet function. Moreover, these data may serve as basis for future developments of PI technologies for PCs. Further studies should address the impact of both the PI and the storage duration on platelets in PCs because PI may enable the extension of the shelf life of PCs by reducing the bacterial contamination risk. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:72 / 83
页数:12
相关论文
共 133 条
[51]   A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1 [J].
Kauskot, Alexandre ;
Di Michele, Michela ;
Loyen, Serena ;
Freson, Kathleen ;
Verhamme, Peter ;
Hoylaerts, Marc F. .
BLOOD, 2012, 119 (17) :4056-4065
[52]   Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction [J].
Kerkhoffs, Jean-Louis H. ;
van Putten, Wim L. J. ;
Novotny, Viera M. J. ;
Boekhorst, Peter A. W. Te ;
Schipperus, Martin R. ;
Zwaginga, Jaap Jan ;
van Pampus, Lizzy C. M. ;
de Greef, Georgine E. ;
Luten, Marleen ;
Huijgens, Peter C. ;
Brand, Anneke ;
van Rhenen, Dick J. .
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (02) :209-217
[53]   Pathogen inactivation technology: cleansing the blood supply [J].
Klein, HG .
JOURNAL OF INTERNAL MEDICINE, 2005, 257 (03) :224-237
[54]   THROMBIN INDUCES ACTIVATION OF P38 MAP KINASE IN HUMAN PLATELETS [J].
KRAMER, RM ;
ROBERTS, EF ;
STRIFLER, BA ;
JOHNSTONE, EM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27395-27398
[55]   p38 Mitogen-activated protein kinase phosphorylates cytosolic phospholipase A(2) (cPLA(2)) in thrombin-stimulated platelets - Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA(2) [J].
Kramer, RM ;
Roberts, EF ;
Um, SL ;
BorschHaubold, AG ;
Watson, SP ;
Fisher, MJ ;
Jakubowski, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (44) :27723-27729
[56]   Existence of a microRNA pathway in anucleate platelets [J].
Landry, Patricia ;
Plante, Isabelle ;
Ouellet, Dominique L. ;
Perron, Marjorie P. ;
Rousseau, Guy ;
Provost, Patrick .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2009, 16 (09) :961-U84
[57]   Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets [J].
Larson, MK ;
Chen, H ;
Kahn, ML ;
Taylor, AM ;
Fabre, JE ;
Mortensen, RM ;
Conley, PB ;
Parise, LV .
BLOOD, 2003, 101 (04) :1409-1415
[58]   Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology [J].
Li, JZ ;
Lockerbie, O ;
de Korte, D ;
Rice, J ;
McLean, R ;
Goodrich, RP .
TRANSFUSION, 2005, 45 (06) :920-926
[59]   Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis [J].
Lian, Lurong ;
Wang, Yanfeng ;
Flick, Matthew ;
Choi, John ;
Scott, Edward W. ;
Degen, Jay ;
Lemmon, Mark A. ;
Abrams, Charles S. .
BLOOD, 2009, 113 (15) :3577-3584
[60]   Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment [J].
Lin, L ;
Conlan, MG ;
Tessman, J ;
Cimino, G ;
Porter, S .
TRANSFUSION, 2005, 45 (10) :1610-1620